A Prescription For Growth: This Med-Tech Turnaround Has Harnessed Market Momentum

In partnership with

Keep This Stock Ticker on Your Watchlist

They’re a private company, but Pacaso just reserved the Nasdaq ticker “$PCSO.”

No surprise the same firms that backed Uber, eBay, and Venmo already invested in Pacaso. What is unique is Pacaso is giving the same opportunity to everyday investors. And 10,000+ people have already joined them.

Created a former Zillow exec who sold his first venture for $120M, Pacaso brings co-ownership to the $1.3T vacation home industry.

They’ve generated $1B+ worth of luxury home transactions across 2,000+ owners. That’s good for more than $110M in gross profit since inception, including 41% YoY growth last year alone.

And you can join them today for just $2.90/share. But don’t wait too long. Invest in Pacaso before the opportunity ends September 18.

Invest While You Still Can

_{Paid advertisement for Pacaso’s Regulation A offering. Read the offering circular at invest.pacaso.com. Reserving a ticker symbol is not a guarantee that the company will go public. Listing on the NASDAQ is subject to approvals.}

30‑Second Take

Why now? Smith & Nephew’s Q2 2025 results show clear momentum, with revenue climbing nearly 8% to $1.55 billion and broad-based growth across orthopedics, sports medicine, and wound care.

Operating profit surged more than 30% year-on-year to $429 million, margins expanded to 17.7%, and adjusted EPS rose 14%.

Crucially, management underscored confidence by launching a $500 million buyback—returning capital while signaling belief in future earnings strength.

With strong cash flow and activist investor oversight pressing for further value creation, Q2 marks a real inflection point, making now an attractive entry opportunity before the turnaround gathers further pace.

Trade Setup

Time frame: Swing to medium-term
Edge type: Momentum breakout

Snapshot Table

Chart

1-Month Synopsis: Over the one month from early August to early September, SNN rallied strongly, gaining 20% driven by sustained investor interest and volume-backed buying.

The stock broke decisively out of the low-$30 range and established a new trading channel between $35 and $37 following strong Q2 figures and an increase in analyst price targets.

Although some short-term technical indicators signal resistance and caution, the longer-term trend remains firmly bullish, especially if the current support level $35 holds on the back of new launches and long-term profit potential.

Bull Case 

Core thesis: Smith & Nephew is a medical technology company focused on developing treatments and products to effectively repair, regenerate, and replace soft and hard tissue. 

The company’s accelerating growth in Q2 2025, marked by nearly 8% revenue expansion, 30% profit growth, and a $500 million buyback, signals that its turnaround strategy is gaining traction.

With structural tailwinds in orthopedics and wound care, improving margins, and activist investor oversight adding pressure for sharper execution, SNN offers investors a blend of operational momentum, shareholder returns, and potential for further value unlocking.

Collectively, these characteristics position the stock as an attractive med-tech recovery play with room to rerate.

Catalysts: The company has this week announced the launch of its new CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient’s own platelets and plasma that may assist the natural healing process.

Proven successful in two clinical trials, the system is designed for use in hospital and physician settings and can be tailored to fit wound shape, depth, and stage with a single draw of a patient’s blood.

Valuation upside: Current price targets point to a high of $41.00 and a low of $34.65. SNN stock is currently trading just a few cents shy of the $37.43 average consensus target.

Technical tailwind: Smith & Nephew’s Relative Strength Rating has climbed into the high-70s in the last week, a sign that momentum investors are increasingly backing the stock’s upward trajectory.

This technical strength, combined with the breakout from its early-August lows into a new $35 – $37 trading channel, suggests a bullish tailwind that could amplify the impact of its improving fundamentals.

Bear Case 

Key risk: A key bear case risk for Smith & Nephew is execution. While margins have improved, sustaining profitability gains in a highly competitive med-tech market will be challenging if cost controls or product launches falter.

In addition, activist pressure and the ongoing turnaround raise expectations, meaning any stumble in growth or guidance could trigger outsized share price volatility.

Macro/sector headwinds: As with other stocks in this sector, SNN faces several broader headwinds, including persistent cost inflation in healthcare supply chains and ongoing pricing pressure from hospital procurement groups.

At the same time, slower elective surgery recovery in specific markets and tightening healthcare budgets could dampen demand, creating a challenging backdrop for med-tech growth despite company-specific progress.

Competitive threat: Rivals like Stryker, Zimmer Biomet, and Johnson & Johnson are investing heavily in innovation and scale advantages, which could prove problematic for SNN.

The significant risk is that stronger pipelines, faster adoption of robotics, or more aggressive pricing strategies from these peers could erode the firm’s market share and limit the impact of its turnaround gains despite its recent progress.

Crowded-trade concern: SNN’s recent positive momentum has attracted a large pool of investors, leaving limited upside if buying pressure slows.

In such a scenario, even minor setbacks in earnings or guidance could trigger amplified volatility as overextended positions unwind.

Quick Checklist 

✅ Thesis still valid after today’s close
✅ Volume confirms move above key levels
✅ Catalyst date double-checked (September 03, 2025)

Deep‑Dive Links

• Q2 2025 Earnings Report 

• Analyst Ratings and Price Targets

• Short Interest Data  

• Company Profile and Investor Relations

That’s all for today’s Everyday Alpha. We’ll have a new pick for you every morning before the market opens, so stay tuned!

Best Regards,
—Noah Zelvis
Everyday Alpha